Servier

GeNeuro to Develop the MS Clinical Program of GNbAC1 Without Servier

GeNeuroĀ announced it has reacquired from Servier the worldwide rights to commercialize and develop the investigational humanized antibodyĀ GNbAC1Ā for the treatment of multiple sclerosis (MS). The decision came after Servier, a European company which, together with GeNeuro, developed the GNbAC1 program, declined to continue developing the therapy due to…

GeNeuro-Servier Antibody Limits RRMS Patients’ Brain Shrinkage, Phase 2b Trial Shows

The laboratory-generated antibodyĀ GNbAC1Ā continued to limitĀ brain shrinkage a year after relapsing-remitting multiple sclerosis patients began receiving it, its developers announced. GeNeuro and ServierĀ were reporting on the 12-month results of aĀ Phase 2b clinical trial. GNbAC1 is a monoclonal antibody that destroys a harmful retroviral protein called pHERV-W which scientists have…

Retroviral RRMS Treatment GNbAC1 Fails Phase 2 Trial, But Research Continues, Say Sponsors

A Phase 2b trial assessingĀ the experimental retroviral-targeting treatment GNbAC1 in patients with relapsing-remitting multiple sclerosis (RRMS) failed to meet its primary goal of reducing brain lesions and other signs of brain inflammation within six months. But researchers at GeNeuro and ServierĀ ā€” the two European companies thatĀ jointly developed the drug…

CHANGE-MS Phase 2 Study Fully Enrolled Early, Results Due in Fall

GeNeuro recently announced that it has finished enrolling multiple sclerosis (MS) patients in the CHANGE-MS Phase 2b Ā studyĀ ā€” several months ahead of schedule.Ā The company nowĀ expects to reportĀ topline results in mid- to late autumn rather than at year’s end. ā€œCompleting enrollment in CHANGE-MS several months sooner than previously anticipated…

MS Patients in Clinical Trial of GNbAC1 May Continue with Therapy in Extension Study

Multiple sclerosis (MS) patients now taking part in a Phase 2b clinical trial testingĀ the efficacy and safety of theĀ antibody GNbAC1Ā will be invited to continue withĀ treatment for two more years under a planned extension study, the biopharmaceutical companiesĀ GeNeuroĀ andĀ ServierĀ recently announced. Several MS therapies rely on the capacity of antibodies to…

#ECTRIMS2016 – GeNeuro Reaches Enrollment Halfway Mark in Study of GNbAC1 to Treat Multiple Sclerosis

GeNeuroĀ announced that it has reached ā€” more quickly than expected ā€” the halfway mark for patient enrollment inĀ itsĀ Phase 2b study, CHANGE-MS,Ā assessingĀ GNbAC1 as a therapy forĀ relapsing-remitting multiple sclerosis (RRMS). Patient recruitmentĀ is continuing at sites across Europe. The company alsoĀ reported onĀ theĀ trial’s design in a poster presentation, “A placebo…

First MS Patients in CHANGE-MS Trial Receive Novel Treatment

GeNeuro, a biopharmaceutical company that focusesĀ on novel treatments for autoimmune diseases such as multiple sclerosis (MS), announced thatĀ the first patients with relapsing-remitting multiple sclerosis (RRMS) are underĀ treatment with the companyā€™s leading drug, GNbAC1, in aĀ Phase 2b clinical trial. GNbAC1 is a monoclonal antibody designed to neutralize MSRV-En, a protein…

Experimental RRMS Therapy to Be Tested in a Phase 2b Clinical Trial

GeNeuro, a company developing therapies for neurological and autoimmune disorders, recently announced the initiation of a Phase 2b clinical trial to assess its lead investigational antibody GNbAC1 in patients with relapsing-remitting multiple sclerosis (RRMS). The trial, called ā€œCHANGE-MS,ā€ plans to enroll 260 patients across 68 centers acrossĀ theĀ European Union and…

GeNeuro and Servier to Co-Develop Breakthrough Multiple Sclerosis Drug

Neurology and autoimmune therapeutics companyĀ GeNeuro SA has just announced the formation of a partnership with independent French pharmaceutical companyĀ ServierĀ for the co-development and marketing of GNbAC1 for Multiple Sclerosis (MS). It is the first humanized monocloncal antibody treatment formulated to address one of this disease’s causal factors, making it…